Previous 10 | Next 10 |
Cellectar Biosciences (NASDAQ: CLRB ) : Q2 GAAP EPS of -$0.26 beats by $0.04 . More news on: Cellectar Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
FLORHAM PARK, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the secon...
FLORHAM PARK, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a poster presentation at the up...
Taoping (NASDAQ: TAOP ) -23% . More news on: Taoping Inc., Precipio, Inc., Socket Mobile, Inc., Stocks on the move, , Read more ...
FSD Pharma (NASDAQ: HUGE ) +130% . on decision to surrender health Canada licenses for subsidiary FV Pharma. More news on: FSD Pharma Inc., Kandi Technologies Group, Inc., Edesa Biotech, Inc., Stocks on the move, , Read more ...
FLORHAM PARK, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a poster presentation at the up...
LM Funding America (NASDAQ: LMFA ) +83% . More news on: LM Funding America, Inc., Myomo, Inc., Electrameccanica Vehicles Corp., Stocks on the move, , Read more ...
FLORHAM PARK, N.J., July 01, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has appointed Dr. John ...
Fuwei Films (NASDAQ: FFHL ) +66% on Q1 results . More news on: Fuwei Films (Holdings) Co., Ltd., Translate Bio, Inc., Recon Technology, Ltd., Stocks on the move, , Read more ...
The European Patent Office issues a composition of matter patent to Cellectar Biosciences ( CLRB -5.8% ) covering the use of phospholipid ether (PLE) analogs as cancer-targeting drug vehicles. More news on: Cellectar Biosciences, Inc., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
17.22%Change Percent:
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40%...
FLORHAM PARK, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the majority of Tranche B warran...
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...